Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.95
CLVS's Cash-to-Debt is ranked lower than
81% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. CLVS: 0.95 )
Ranked among companies with meaningful Cash-to-Debt only.
CLVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.95  Med: No Debt Max: No Debt
Current: 0.95
Piotroski F-Score: 1
Altman Z-Score: -1.79
Beneish M-Score: -5.04
WACC vs ROIC
17.72%
-1036.64%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -249.54
CLVS's ROE % is ranked lower than
91% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. CLVS: -249.54 )
Ranked among companies with meaningful ROE % only.
CLVS' s ROE % Range Over the Past 10 Years
Min: -249.54  Med: -83.7 Max: -26.78
Current: -249.54
-249.54
-26.78
ROA % -67.42
CLVS's ROA % is ranked lower than
74% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CLVS: -67.42 )
Ranked among companies with meaningful ROA % only.
CLVS' s ROA % Range Over the Past 10 Years
Min: -144.39  Med: -51.12 Max: -21.25
Current: -67.42
-144.39
-21.25
ROC (Joel Greenblatt) % -7707.96
CLVS's ROC (Joel Greenblatt) % is ranked lower than
84% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. CLVS: -7707.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CLVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9748.56  Med: -7941.19 Max: -3834.63
Current: -7707.96
-9748.56
-3834.63
3-Year EBITDA Growth Rate 48.70
CLVS's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. CLVS: 48.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CLVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.4  Med: 8.65 Max: 51.8
Current: 48.7
-53.4
51.8
3-Year EPS without NRI Growth Rate 45.40
CLVS's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CLVS: 45.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CLVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.1  Med: 7.15 Max: 48.8
Current: 45.4
-53.1
48.8
GuruFocus has detected 3 Warning Signs with Clovis Oncology Inc $CLVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CLVS's 10-Y Financials

Financials (Next Earnings Date: 2017-05-22 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CLVS Guru Trades in Q1 2016

Jim Simons 515,400 sh (New)
Kyle Bass 100,000 sh (New)
Steven Cohen 603,100 sh (unchged)
Paul Tudor Jones 13,858 sh (-93.84%)
» More
Q2 2016

CLVS Guru Trades in Q2 2016

Paul Tudor Jones Sold Out
Kyle Bass Sold Out
Jim Simons 307,200 sh (-40.40%)
» More
Q3 2016

CLVS Guru Trades in Q3 2016

Columbia Wanger 204,000 sh (New)
Louis Moore Bacon 95,000 sh (New)
Jim Simons Sold Out
» More
Q4 2016

CLVS Guru Trades in Q4 2016

John Burbank 381,814 sh (New)
Jim Simons 82,100 sh (New)
Chuck Royce 76,000 sh (New)
Columbia Wanger 189,958 sh (-6.88%)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:RARE, NAS:ICPT, NAS:NKTR, OTCPK:BTGGF, NAS:CBPO, NAS:BLUE, NAS:GLPG, NAS:TECH, NAS:AGIO, NAS:SAGE, NYSE:XON, NAS:LGND, NAS:PTLA, OTCPK:ABCZY, NAS:JUNO, NAS:AVXS, NAS:ACAD, NAS:KITE, NAS:PRTA, NAS:TBPH » details
Traded in other countries:C6O.Germany,
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.

Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.

Top Ranked Articles about Clovis Oncology Inc

Kyle Bass Purchases Stake in Clovis Oncology Company has been aiming for FDA approval for its lung cancer drug
During the first quarter guru Kyle Bass (Trades, Portfolio) purchased 100,000 shares of Clovis Oncology Inc. (NASDAQ:CLVS). Read more...

Ratios

vs
industry
vs
history
Current Ratio 4.26
CLVS's Current Ratio is ranked higher than
52% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CLVS: 4.26 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 4.26  Med: 10.28 Max: 15.68
Current: 4.26
4.26
15.68
Quick Ratio 4.26
CLVS's Quick Ratio is ranked higher than
54% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CLVS: 4.26 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 4.26  Med: 10.28 Max: 15.68
Current: 4.26
4.26
15.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.50
CLVS's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CLVS: -4.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CLVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -194.7  Med: -14.2 Max: -4.5
Current: -4.5
-194.7
-4.5

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -12.74
CLVS's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. CLVS: -12.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CLVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -584.77  Med: 0 Max: 0
Current: -12.74
-584.77
0

More Statistics

EPS (TTM) $ -9.07
Beta2.19
Short Percentage of Float23.17%
52-Week Range $11.57 - 74.94
Shares Outstanding (Mil)44.63
» More Articles for CLVS

Headlines

Articles On GuruFocus.com
Kyle Bass Purchases Stake in Clovis Oncology May 25 2016 
Kyle Bass Builds Bull Case for Clovis Oncology Nov 27 2015 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 

More From Other Websites
AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA Mar 29 2017
[$$] Overheard Mar 28 2017
5:28 pm Clovis Oncology announces four data presentations for AACR April 1-5 Meeting that will... Mar 28 2017
Clovis Oncology Announces Data Presentations at AACR Annual Meeting 2017 Mar 28 2017
Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer Mar 28 2017
Biotech M&A Trade Hits a Snag Mar 28 2017
BUZZ-AstraZeneca cancer drug faces new competition from Tesaro Mar 28 2017
Why Is Clovis (CLVS) Up 18.8% Since the Last Earnings Report? Mar 28 2017
Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely Mar 27 2017
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of the Board of... Mar 24 2017
Look for Clovis Oncology to Resume Its Advance Mar 20 2017
5 Biotech Companies To Watch In 2017 Mar 17 2017
5 Biotech Companies Set for Major Breakouts In 2017 Mar 17 2017
AstraZeneca PLC (ADR) (AZN)’s Lynparza Trial Results Positive In Competitive Threat To Clovis... Mar 16 2017
3 tech and biotech stocks with momentum Mar 16 2017
Tesaro Sell-Off On AstraZeneca Ovarian Cancer Trial Overdone: Analyst Mar 15 2017
Here’s What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology... Mar 15 2017
Lynparza Vs. Niraparib Mar 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)